X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (33) 33
index medicus (29) 29
humans (23) 23
cancer (21) 21
female (17) 17
male (17) 17
middle aged (17) 17
aged (16) 16
clinical trials (12) 12
adult (11) 11
neoplasms - drug therapy (11) 11
survival (11) 11
patients (10) 10
aged, 80 and over (9) 9
antineoplastic agents - adverse effects (9) 9
immunotherapy (9) 9
treatment outcome (9) 9
tumors (9) 9
chemotherapy (8) 8
solid tumors (8) 8
toxicity (8) 8
antineoplastic agents - therapeutic use (7) 7
lung neoplasms - drug therapy (7) 7
docetaxel (6) 6
expression (6) 6
lung cancer (6) 6
open-label (6) 6
pharmacology & pharmacy (6) 6
research (6) 6
respiratory system (6) 6
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
care and treatment (5) 5
disease control (5) 5
gemcitabine (5) 5
melanoma (5) 5
metastasis (5) 5
nivolumab (5) 5
nsclc (5) 5
risk factors (5) 5
safety (5) 5
safety engineering (5) 5
therapy (5) 5
trastuzumab (5) 5
young adult (5) 5
[ sdv.can ] life sciences [q-bio]/cancer (4) 4
analysis (4) 4
anticancer properties (4) 4
cell lung-cancer (4) 4
drug development (4) 4
drug therapy (4) 4
inhibitors (4) 4
lung cancer, non-small cell (4) 4
medical research (4) 4
medicine & public health (4) 4
mutation (4) 4
non-small cell lung carcinoma (4) 4
pembrolizumab (4) 4
pharmacokinetics (4) 4
pharmacology (4) 4
pharmacology/toxicology (4) 4
phase i trial (4) 4
prognosis (4) 4
adenocarcinoma - drug therapy (3) 3
afatinib (3) 3
albumin (3) 3
antineoplastic agents - administration & dosage (3) 3
cancer patients (3) 3
cancer therapies (3) 3
clinical trials, phase i as topic (3) 3
complications and side effects (3) 3
deoxycytidine - analogs & derivatives (3) 3
dosage and administration (3) 3
drug administration schedule (3) 3
experience (3) 3
hematology, oncology and palliative medicine (3) 3
immune checkpoint (3) 3
immune checkpoint blockade (3) 3
life sciences (3) 3
medicine, experimental (3) 3
mesothelioma (3) 3
metastases (3) 3
molecular targeted therapy (3) 3
neoplasms - mortality (3) 3
prognostic score (3) 3
protein kinase inhibitors - adverse effects (3) 3
protein kinase inhibitors - therapeutic use (3) 3
targeted therapy (3) 3
1-phosphatidylinositol 3-kinase (2) 2
1st-line treatment (2) 2
abstracts (2) 2
adenocarcinoma (2) 2
adenocarcinoma - genetics (2) 2
alterations (2) 2
angiogenesis (2) 2
anti-pd-l1 antibody (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 05/2019, Volume 120, Issue 10, pp. 975 - 981
BACKGROUND: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. METHODS: This dose-finding... 
MIGRATION | CRITERIA | ACTIVATION | ONCOLOGY | BENIGN | MESOTHELIOMA | EXPRESSION | CANCER | Appetite | Pharmacodynamics | Toxicity | Diarrhea | Mesothelioma | Nausea | Pharmacology | Exposure | Pruritus | Kinases | Disease control | Adhesion | Anticancer properties | Inhibitors | Protein kinase | Safety engineering | Focal adhesion kinase | Solid tumors | Pharmacokinetics | Tumors | Index Medicus | Oncology
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 06/2017, Volume 79, Issue 6, pp. 1257 - 1265
This phase I trial evaluated the safety and tolerability of milciclib, an inhibitor of multiple cyclin-dependent kinases and tropomycin receptor kinase A, in... 
Advanced cancer patient | Cyclin-dependent kinase inhibitors | Gemcitabine | Milciclib | TROPOMYOSIN RECEPTOR KINASE | PANCREATIC-CANCER | TRK | CHEMOTHERAPY | ONCOLOGY | PHARMACOLOGY & PHARMACY | CELL-CYCLE | SINGLE-AGENT GEMCITABINE | INHIBITOR | PROTEINS | Lung Neoplasms - drug therapy | Deoxycytidine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antimetabolites, Antineoplastic - administration & dosage | Neoplasms - drug therapy | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Drug Interactions | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Cyclin-Dependent Kinases - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Pancreatic cancer | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Phosphotransferases | Thrombocytopenia | Toxicity | Cyclin-dependent kinases | Oral administration | Medical services | Non-small cell lung carcinoma | Mesothelioma | Pharmacology | Kinases | Patients | Pancreatic carcinoma | Quality | Safety engineering | Ataxia | Safety | Solid tumors | Tremors | Pharmacokinetics | Tumors | Thyroid | Neutropenia | Peritoneum | Index Medicus
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 8/2018, Volume 36, Issue 4, pp. 619 - 628
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2018, Volume 36, Issue 1, pp. 62 - 74
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2017, Volume 35, Issue 1, pp. 79 - 86
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 85, p. 155
The case of a 58-year-old male patient with 40 pack-year history of smoking, presenting KRAS-mutant metastatic lung adenocarcinoma, is discussed. The patient... 
Adenocarcinoma | Lung cancer | Non-small cell lung carcinoma | Metastasis | Patients | Mimicry | Metastases | Chemotherapy | Lungs | Platinum | Immunotherapy | Differential diagnosis | Diagnosis | Smoking
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 391 - 391
Abstract BACKGROUND: Hairy cell leukemia is a rare, indolent, B-cell lymphoproliferative disease characterized by the BRAF V600E mutation in 90% to 100% of... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2019, Volume 25, Issue 3, pp. 946 - 956
Purpose: Anti-PD-(L) 1 can provide overall survival (OS) benefits over conventional treatments for patients with many different cancer types. However, the... 
NEOANTIGEN LANDSCAPE | ANTI-PD-L1 ANTIBODY | PEMBROLIZUMAB | ONCOLOGY | IMMUNOTHERAPY | PD-1 BLOCKADE | ACQUIRED-RESISTANCE | PROGNOSTIC SCORE | PHASE-I | CANCER | CELL-DEATH
Journal Article